Surfing The NASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

most recent episode ⤵

S4-5.6 - From the VAULT: Patient Follow-Up Challenges in Modeling NASH Diagnostics

S4-5.6 – From the VAULT: Patient Follow-Up Challenges in Modeling NASH Diagnostics

This episode From the Vault comes from Season 3, Episode 39.4. Ian Rowe’s decision curve model does an excellent job of modeling the success rate and cost effectiveness of modeling early NASH diagnosis. However, as Louise Campbell points out, simply getting the patient diagnosed does not mean therapeutic success, which has implications for the early diagnosis model and broader patient management issues.

SurfingNASH.Com is honored to have the following sponsors

S4-4 – Surfing NASH Audience Reacts to NASH-TAG and the Future of Fatty Liver

The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. Respectively, Pamela Danagher (Terns Pharma), Jerry Mabary (Chronwell) and Caitlin Schneider (Sonic Incytes) join Jörn Schattenberg and Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.

This is truly an excellent podcast…(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke University), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology
FINALLY!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!
I learn without trying(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.
At Long Last!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.

Experience Nudge Learning! Interested in a new way of learning?